KRAS and non-small cell lung carcinoma: In 2025, Jänne et al. reported the largest first-line dataset testing a KRAS-G12C inhibitor with PD-(L)1 blockade, evaluating adagrasib plus pembrolizumab in advanced or metastatic KRAS-G12C NSCLC.